Stage III Lung Cancer AJCC v8
Oncology·MeSH: Lung Neoplasms
Prevalence
30.0 / 100K
2 drugs in development·2 companies·8 clinical trials
Drug Pipeline by Phase
Phase 3(1)
| Drug | Company |
|---|---|
| Pemetrexed | ENANTA PHARMACEUTICALS INC (ENTA) |
Phase 1(1)
| Drug | Company |
|---|---|
| Pemetrexed | ADMA BIOLOGICS, INC. (ADMA) |
Frequently asked questions
How many drugs are in development for Stage III Lung Cancer AJCC v8?
BioSniper tracks 2 drugs in development for Stage III Lung Cancer AJCC v8 across 2 companies.
How many clinical trials target Stage III Lung Cancer AJCC v8?
There are 8 clinical trials targeting Stage III Lung Cancer AJCC v8 tracked by BioSniper.
What is the prevalence of Stage III Lung Cancer AJCC v8?
The estimated prevalence of Stage III Lung Cancer AJCC v8 is approximately 30.0 per 100,000 population.
Deep-dive into Stage III Lung Cancer AJCC v8
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis